Let’s Help Bring Back the ALS Clinics

As I hung up the phone following a short chat with my neurologist, an old saying bubbled up in my mind: “You don’t know what you’ve got until it’s gone.” What was I bemoaning the loss of? My ALS clinic. I’ve been missing the interaction, the idea-sharing, and being…

As a new U.S. Congress prepares to start the annual process of determining funding for federal programs, the ALS Association is asking its advocacy network to press their legislators to expand support for research in amyotrophic lateral sclerosis (ALS). “This year, the ALS Association will aggressively pursue new and…

Abnormalities in the activity of the protein TDP-43, whose gene is often mutated in amyotrophic lateral sclerosis (ALS), can increase DNA damage in cells, a study shows. These findings shed light on the molecular underpinnings of ALS, and may open new avenues for treatment, its researchers said. The study,…

People with amyotrophic lateral sclerosis (ALS) who use melatonin have better survival outcomes and experience slower disease progression, a new analysis indicates. The findings suggest that melatonin may be beneficial for people with ALS. However, because the analysis was not designed to find cause-and-effect relationships, further studies are needed,…

It’s hard to find guides for the grief that accompanies a long, progressive terminal illness. Loss is often talked about as an event that happened in the past. It’s difficult to process grief when you know you haven’t reached the bottom yet, when the losses keep coming. In Brené Brown’s…

Work into moving M102, an investigative treatment for amyotrophic lateral sclerosis (ALS), into testing in people has been given a boost by a £1.6 million research grant awarded to Aclipse Therapeutics and the…

“Oh yes, I am wise, but it’s wisdom born of pain. — “I Am Woman,” Helen Reddy “Gain from pain” is not a new concept. The notion can be traced back several millennia to “The Ethics of the…

A patent application allowing MediciNova to use its investigational therapy ibudilast (MN-166) in combination with riluzole to treat people with amyotrophic lateral sclerosis (ALS) has been approved for issue in Japan. The patent request filed with the Japan Patent Office covers a wide range of oral doses and dosing…

I’ve always believed in the importance of having heroes and role models to help me cope with ALS. In fact, I keep a list of names in a special folder titled “ALS Inspiration.” But most of the people on my list don’t even have ALS. What they do have in common…

Mitsubishi Tanabe Pharma America (MTPA) has entered an agreement with Aquestive Therapeutics to market Exservan, an oral film formulation of riluzole, for treating amyotrophic lateral sclerosis (ALS) in the United States. Under terms of the agreement, Aquestive — the developer of Exservan — will be the exclusive manufacturer and…